a Department of Dermatology and Center for Chronic Pruritus , University Hospital Münster , Münster , Germany.
Expert Opin Investig Drugs. 2018 Dec;27(12):981-988. doi: 10.1080/13543784.2018.1548606. Epub 2018 Nov 19.
Chronic pruritus (CP) is a multidimensional condition severely affecting the quality of life of those affected. Although a multitude of topical and systemic agents are recommended for CP of different origins, the condition often remains refractory to treatment. However, a deeper understanding of the pathophysiology of CP is leading to the development of novel antipruritic drugs.
This paper reviews antipruritic therapies in development by gathering data from recently published articles and clinical trials databases. Interleukin-31 antibodies and other biologics, neurokinin-1 receptor antagonists, opioid-receptor agonists/antagonists, TrkA-antagonists, and ileal bile acid transporter inhibitors are discussed.
Clinical trials have rendered promising data on the antipruritic efficacy and safety of novel drugs, but further studies are necessary to enhance our understanding of the different conditions associated with CP. High-quality clinical trial data is necessary for these agents to be approved for the treatment. Basic research should be intensified to identify pathways relevant for CP and to further the development of new specific antipruritic drugs.
慢性瘙痒症（CP）是一种多维疾病，严重影响受影响者的生活质量。尽管有许多推荐的局部和全身药物用于不同来源的 CP，但该疾病通常仍然对治疗有抗药性。然而，对 CP 病理生理学的更深入了解正在导致新型止痒药物的开发。
本文通过从最近发表的文章和临床试验数据库中收集数据，综述了正在开发中的止痒疗法。讨论了白细胞介素-31 抗体和其他生物制剂、神经激肽-1 受体拮抗剂、阿片受体激动剂/拮抗剂、TrkA 拮抗剂和回肠胆汁酸转运蛋白抑制剂。
临床试验在新型药物的止痒疗效和安全性方面提供了有希望的数据，但需要进一步研究以加深我们对与 CP 相关的不同情况的理解。这些药物需要高质量的临床试验数据才能获得批准用于治疗。应加强基础研究，以确定与 CP 相关的途径，并进一步开发新的特异性止痒药物。
